FT-104 (4-glutaryloxy-N,N-diisopropyltryptamine) is a psychedelic tryptamine derivative which is a prodrug ester of the well known designer drug 4-HO-DiPT. It is one of a number of related derivatives developed for potential medical applications, and is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression.[1][2][3][4]
![]() | |
Clinical data | |
---|---|
Other names | RE-104 |
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C21H30N2O |
Molar mass | 326.484 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104". 11 August 2022.
- ^ Bryson N. Tryptamine Prodrugs. Patent WO 2022/000091
- ^ Slassi A, Araujo J. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders. Patent application US 2022/0024956
- ^ Slassi A, et al. Hallucinogen-Fatty Acid Combination. Patent WO 2022/246572